Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

ber 31, 2006. Shire has the leading portfolio of products in the US ADHD market.

PENTASA - Ulcerative colitis

US prescriptions of PENTASA for the year to December 31, 2007 were up 3% compared to the same period in 2006 primarily due to a 4% increase in the US oral mesalamine prescription market, offset by a 0.1% decrease in PENTASA's average market share from 17.3% in 2006 to 17.2% in 2007.

Sales of PENTASA for the year to December 31, 2007 were US$176.4 million, an increase of 28% compared to the same period in 2006 (2006: US$137.8 million). Sales growth is higher than prescription growth primarily due to restocking to normal levels in 2007 and the impact of price increases in November 2006 and August 2007.

LIALDA/MEZAVANT - Ulcerative colitis

Shire launched LIALDA in the US oral mesalamine market in March 2007, and by December 31, 2007 LIALDA had reached a market share of 8.0% (average annual market share 3.9%). LIALDA's product sales for the year to December 31, 2007 were US$50.5 million. All initial launch stocks of LIALDA totaling US$34.3 million were recognised into revenue during the year to December 31, 2007.

The product was launched in the UK in November 2007, Canada in January 2008 and further launches are planned in the EU during 2008, subject to the successful conclusion of pricing and reimbursement negotiations. In the UK and Ireland the product will be called MEZAVANT XL and Shire plans to market the product in most other EU countries as MEZAVANT.

Since the launch of LIALDA in March 2007, PENTASA and LIALDA's combined share of the US oral mesalamine prescription market had grown to 24.9% as at December 31, 2007, up from 17.6% as at December 31, 2006.

FOSRENOL - Hyperphosphatemia

FOSRENOL is now available in 25 countries and global sales totalled US$102.2 million for the year to December 31, 2007 (2006: US$44.8 million). Outside the US, FOSRENOL has now been launched in Germany, France, UK,
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... (PRWEB) October 24, 2014 Today, Nerium ... announced the winners of its “Reflect Your Youth” contest, ... not only seen a difference in their skin since ... a new outlook on life as a result of ... originated as an effort by Nerium International to inspire ...
(Date:10/25/2014)... NEW YORK , Oct. 24, 2014 ... Access Pharmaceuticals, Inc. (ACCP), a biopharmaceutical company advancing ... implemented a 1-for-50 reverse split of its common ... Friday, October 24, 2014. PlasmaTech,s common stock will ... number 72754H109 and temporary ticker symbol "ACCPD". After ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... growth in the in vitro diagnostic (IVD) test industry, ... Kalorama Information. The healthcare market researcher listed more than 25 ... that could be the future of IVD products. Kalorama details ... industry, The Worldwide Market for In Vitro Diagnostic ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open ... the pain management and clinical markets. The software increases ... by allowing users to highlight and review results that ... allows analysts to filter results by group or based ... eliminating the need to sift through analytes of no ...
Breaking Biology Technology:Nerium International™ Inspires Conversation About the Journey of Aging with “Reflect Your Youth” Contest 2PlasmaTech Biopharmaceuticals, Inc. Announces Reverse Stock Split, Ticker Change and Launches New Corporate Website 2Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2
... reduced and Semen Sexing Technology achieves, milestone, ... months ended June 30, 2009, Microbix Biosystems Inc. (TSX:MBX) announced ... quarter had a small sales retraction that was related to ... for continued growth in sales. , "The 22% sales growth ...
... , , ... SIAL ) today announced the acquisition of cheminformatics ... informatics software tools used for design, selection and procurement ... www.chemnavigator.com ) comprehensive suite of virtual screening ...
... , , , , ... SQNM ), today reported its financial results for the quarter ended June ... Second Quarter Results , , ... $12.8 million for the second quarter of 2008. The decrease from the comparable ...
Cached Biology Technology:Microbix Sales Grow 22% For Nine Months 2Microbix Sales Grow 22% For Nine Months 3Microbix Sales Grow 22% For Nine Months 4Microbix Sales Grow 22% For Nine Months 5Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services 2Sigma-Aldrich Acquires ChemNavigator, Inc., to Provide Researchers With Industry-Leading Chemical Compound Selection and Procurement Services 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 2SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 3SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 4SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 5SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 6SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 7SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 8SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 9SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights 10
(Date:10/18/2014)... referred for evaluation of suspected genetic conditions, whole-exome ... percent, including detection of a number of rare ... according to a study appearing in JAMA ... with the American Society of Human Genetics annual ... coding regions of thousands of genes simultaneously using ...
(Date:10/17/2014)... available in German . ... few drugs. When treating overdoses, doctors are often limited to ... if there is a combination of drugs involved. So what ... swallows his grandmother,s pills? ETH professor Jean-Christophe Leroux from the ... an answer to this question. "The task was to develop ...
(Date:10/16/2014)... they are anything but sustainable: environmental damage to ... becoming increasingly evident. Despite their disadvantages, however, monocultures ... as the sole possibility of achieving higher yields ... Schmid, an ecology professor at the University of ... and forestry. After all, a new study carried ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... ancient genes, scientists have for the first time reconstructed ... system. , The research was led by Joe Thornton, ... Center for Ecology and Evolutionary Biology, and will be ... How natural selection can drive the evolution of complex ...
... them study endangered whales ?autonomous hydrophones that can be deployed ... calls of different whale species. , Those efforts are leading ... of researchers of rare right whales swimming in the Gulf ... of a right whale in the Gulf of Alaska since ...
... generation of artificial bone may rely on a few ... of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have ... scaffolding-like material that is four times stronger than material ... the investigational stages, variations of this substance could also ...
Cached Biology News:Evolution of 'irreducible complexity' explained 2Research tracks whales by listening to sounds 2Research tracks whales by listening to sounds 3Secrets of the sea yield stronger artificial bone 2Secrets of the sea yield stronger artificial bone 3Secrets of the sea yield stronger artificial bone 4